Using a Panel of Heat Shock Proteins for Diagnosis and Prognosis of Breast Cancer

Ebtsam R. Zaher^1, , Mahmoud A. Hemida², Mohammad M. El-Hashash² and Heba G. El-Sheridy³

¹Radiation Sciences Department, Medical Research Institute, Alexandria University, Alexandria, Egypt

²Experimental and Clinical Surgery Department, Medical Research Institute, Alexandria University, Alexandria, Egypt

³Cancer Management and Research Department, Medical Research Institute, Alexandria University, Alexandria, Egypt

Cite this paper:
Ebtsam R. Zaher, Mahmoud A. Hemida, Mohammad M. El-Hashash and Heba G. El-Sheridy. Using a Panel of Heat Shock Proteins for Diagnosis and Prognosis of Breast Cancer. Journal of Cancer Research and Treatment. 2018; 6(2):47-53. doi: 10.12691/jcrt-6-2-4

Abstract

Purpose: The current work aimed to evaluate the diagnostic and prognostic role of a panel of heat shock proteins; HSP27, HSP60, HSP70 and HSP90, in sera of breast cancer patients, in comparison with CA 15.3 as the standard marker in breast cancer management. Methodology: The study included 248 females diagnosed with primary breast cancer and 232 normal healthy females. Patients were managed by modified radical mastectomy or breast conservative surgery then received adjuvant therapy and clinically followed up for 5 years. In sera of all patients and controls; HSP27, HSP60, HSP70 and HSP90 were measured by ELISA while CA 15.3 was measured by IRMA. Findings: Pre-treatment serum levels of HSP27, HSP60, HSP70 and HSP90 were significantly elevated in breast cancer patients than in controls, furthermore, they were significant as diagnostic markers, especially when using a panel of HSP70≥9.2 ng/ml and HSP60≥7.5 ng/ml with AUC, sensitivity and specificity of 0.995, 98% and 95%; respectively. As prognostic markers, patients with elevated serum HSP27, HSP60 or HSP70 had significantly lower DFS than patients having lower serum levels. In addition, in patients with at least two HSPs of the three above their cutoffs, the HR increased to 4.65, and it jumped to 17.88 for patients having all three HSPs elevated above their respective cutoff values. CA 15.3 was not significant as diagnostic or prognostic marker. Conclusion: A panel of pre-treatment serum HSP70≥9.2 ng/ml and HSP60≥7.5 ng/ml may be useful for screening of populations at high risk of developing breast cancer. For prediction of treatment response, patients who have elevated pre-treatment serum HSP27, HSP60 or HSP70 had significantly lower DFS. In addition, the risk of relapse in patients having at least two HSPs and patients having all three HSPs elevated above their respective cutoffs were 4.65-times and 17.88-times that of patients with HSPs below their respective cutoffs.

Keywords:
breast cancer heat shock proteins diagnosis prognosis

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Azim, H.A. and Ibrahim, A.S, “Breast cancer in Egypt, China and Chinese: statistics and beyond”, Journal of Thoracic Diseases, 6(7), 864-866, July 2014.
[2]	Welch, H.G., Prorok, P.C., O’Malley, A.J. and Kramer, B.S, “Breast-cancer tumor size, over diagnosis, and mammography screening effectiveness”, New England Journal of Medicine, 375(15), 1438–1447, October 2016.
[3]	Calderwood, S.K., Khaleque, M.A., Sawyer, D.B. and Ciocca, D.R, “Heat shock proteins in cancer: chaperones of tumorigenesis”, Trends in Biochemical Sciences, 31(3), 164-172, Mars 2006.
[4]	Hightower, L.E. and Guidon, P.TJr, “Selective release from cultured mammalian cells of heat shock (stress) proteins that resemble glia-axon transfer proteins”, Journal of Cellular Physiology, 138(2), 257-266, February 1989.
[5]	Giuliano, A.E., Connolly, J.L., Edge, S.B., Mittendorf, E.A., Rugo, H.S., Solin, L.J., Weaver, L.D., Winchester, J.D. and Hortobagyi, N.G, “Breast Cancer—Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual” CA: A Cancer Journal for Clinicians, 67(4), 290-303. July 2017.
[6]	Sainsbury, R, Breast. In, Kirk, R.M. and Winslet, M.C, General Surgical Operations, 5th ed. Churchill Livingstone Elsevier, 2006, 370-383.
[7]	Haskell, C.M, Breast cancer. In, Casciato, D.A, Manual of Clinical Oncology, 6th ed., Lippincott Williams and Wilkins, USA, 2004, 218-37.
[8]	Verghese, J., Abrams, J., Wang, Y. and Morano, K.A, “Biology of the heat shock response and protein chaperones: budding yeast (Saccharomyces cerevisiae) as a model system”, Microbiology and Molecular Biology Reviews, 76(2), 115-58, June 2012.
[9]	De Maio, A, “Heat shock proteins: Facts, thoughts, and dreams”, Shock, 11(1), 1-12, January 1999
[10]	Kampinga, H.H., Hageman, J., Vos, M.J., Kubota, H., Tanguay, R.M., Bruford, E.A., Cheetham, M.E., Chen, B. and Hightower, L.E, “Guidelines for the nomenclature of the human heat shock proteins”, Cell Stress Chaperones, 14(1), 105-11, January 2009.
[11]	Welch, W.J, “Mammalian stress response: cell physiology, structure/function of stress proteins, and implications for medicine and disease”, Physiological Reviews, 72(4), 1063-1081, October 1992.
[12]	Malinovska, L., Kroschwald, S., Munder, M.C., Richter, D. and Alberti, S, “Molecular chaperones and stress-inducible protein-sorting factors coordinate the spatiotemporal distribution of protein aggregates”, Molecular Biology of the Cell, 23(16), 3041-3056, August 2012.
[13]	Wheeler, D.S. and Wong, H.R, “Heat shock response and acute lung injury” Wheeler, Derek S., and Hector R. Wong. “The Heat Shock Response and Acute Lung Injury.” Free radical biology and medicine, 42(1), 1-14, February 2007.
[14]	De Maio, A. and Vazquez, D, “Extracellular heat shock proteins: a new location, a new function”, Shock, 40(4), 239-246, October 2013.
[15]	Giuliano, J.SJr., Lahni, P.M., Wong, H.R. and Wheeler D.S, “Extracellular Heat Shock Proteins: Alarmins for the Host Immune System”, The Open Inflammation Journal, 4, 49-60, October 2011.
[16]	Della Salda, L. and Romanucci, M, “The Role of Heat Shock Proteins in Mammary Neoplasms: A Brief Review”, Journal of Cancer Therapy, 3(5A), 755-767, October 2012.
[17]	Tang, D., Khaleque, A.A., Jones, E.R., Theriault, J.R., Li, C., Wong, W.H., Stevenson, M.A. and Calderwood, S.K,“Expression of heat shock proteins and HSP messenger ribonucleic acid in human prostate carcinoma in vitro and in tumors in vivo” Cell Stress Chaperones, 10(1), 46-59, Mars 2005.
[18]	Ciocca, D.R. and Calderwood, S.K,”Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications”, Cell Stress Chaperones, 10(2), 86-103, June 2005.
[19]	Fanelli, M.A., Cuello Carrión, F.D., Dekker, J., Schoemaker, J. and Ciocca, D.R, “Serological detection of heat shock protein hsp27 in normal and breast cancer patients”, Cancer epidemiology, biomarkers and prevention, 7(9), 791-795, September 1998.
[20]	Desmetz, C., Bibeau, F., Boissière, F, .Bellet, V., Rouanet, P., Maudelonde, T., Mangé, A., Solassol, J. “Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ”, Journal of Proteome Research, 7(9), 3830-3837, September 2008.
[21]	Gunaldi, M., Afsar, C.U., Okuturlar, Y., Gedikbasi, A., Kocoglu, H., Kural, A., Akarsu, C., Gunduz, U. and Tiken, E.E. “Elevated serum levels of heat shock protein 70 are associated with breast cancer” Tohoku Journal of Experimental Medicine, 236(2), 97-102, June 2015.
[22]	Kazarian, A., Blyuss, O., Metodieva, G., Gentry-Maharaj, A., Ryan, A., Kiseleva, E.M., Prytomanova, O.M., Jacobs, I.J., Widschwendter, M., Menon, U. and Timms, J.F, “Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples”, British Journal of Cancer, 116(4), 501-508, February 2017.
[23]	Seigneuric, R., Mjahed, H., Gobbo, J., Joly, A.L., Berthenet, K., Shirley, S. and Garrido, C, “Heat Shock Proteins as Danger Signals for Cancer Detection”, Frontiers in Oncology, 1, 37, November2011
[24]	Santos, T.G., Martins, V.R., Hajj, J.N.M, “Unconventional Secretion of Heat Shock Proteins in Cancer” International Journal of Molecular Sciences, 18(5), E946, April 2017.
[25]	Nahleh, Z., Tfayli, A., Najm, A., El Sayed, A. and Nahle, Z, “Heat shock proteins in cancer: targeting the 'chaperones'”, Future Medicinal Chemistry, 4(7), 927-935, May 2012.
[26]	Miyata, Y., Nakamoto, H. and Neckers, L, “The therapeutic target Hsp90 and cancer hallmarks”, Current Pharmaceutical Design, 19(3), 347-365, 2013.
[27]	Chatterjee, S. and Burns, T.F, “Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach”, International Journal of Molecular Sciences, 18(9), 1978, September 2017.
[28]	De, A.K., Banerjee, S., Lin, C.F., Skinner, K., Schiffhauer, L., Peacock, J., Huston, A., Shayne, M., Strickland, J. and O'Donoghue, L, “Serum Hsp27 levels may serve as a prognostic biomarker in patients with localized breast cancer: A preliminary report” In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 17-21 Apr 2010; Washington, DC. Philadelphia (PA): AACR; Cancer Research 2010; 70(8 Suppl): Abstract nr 882.
[29]	Arrigo, A.P., Paul, C., Ducasse, C., Manero, F., Kretz-Remy, C., Virot, S., Javouhey, E., Mounier, N. and Diaz-Latoud, C, “Small stress proteins: novel negative modulators of apoptosis induced independently of reactive oxygen species”, Progress in Molecular and Subcellular Biology, 28, 185-204, 2002.
[30]	Ciocca, D.R., Rozados, V.R., Cuello-Carrio F.D., Gervasoni, S.I., Matar, P. and Scharovsky, O.G, “Heat shock proteins 25 and 70 in rodent tumors treated with doxorubicin and lovastatin”, Cell Stress Chaperones, 8(1), 26-36, January 2003.
[31]	Nadin, S., Vargas-Roig, L.M., Cuello-Carrio F.D. and Ciocca, D.R, “Deoxyribonucleic acid damage induced by doxorubicin in peripheral blood mononuclear cells: possible roles for the stress response and the deoxyribonucleic acid repair process”, Cell Stress Chaperones, 8(4), 361-371, October 2003.